期刊
NEUROPSYCHOPHARMACOLOGY
卷 35, 期 11, 页码 2143-2154出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2010.105
关键词
glycogen synthase kinase-3; lithium; molecular and cellular neurobiology; mood disorders; neuropharmacology; signal transduction
资金
- NIH [MH73723, MH86622, MH38752]
- NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH086622, R01MH073723, R56MH038752, R01MH038752] Funding Source: NIH RePORTER
Little is known regarding the mechanisms underlying the complex etiology of mood disorders, represented mainly by major depressive disorder and bipolar disorder. The 1996 discovery that lithium inhibits glycogen synthase kinase-3 (GSK3) raised the possibility that impaired inhibition of GSK3 is associated with mood disorders. This is now supported by evidence from animal biochemical, pharmacological, molecular, and behavioral studies and from human post-mortem brain, peripheral tissue, and genetic studies that are reviewed here. Mood disorders may result in part from impairments in mechanisms controlling the activity of GSK3 or GSK3-regulated functions, and disruptions of these regulating systems at different signaling sites may contribute to the heterogeneity of mood disorders. This substantial evidence supports the conclusion that bolstering the inhibitory control of GSK3 is an important component of the therapeutic actions of drugs used to treat mood disorders and that GSK3 is a valid target for developing new therapeutic interventions. Neuropsychopharmacology (2010) 35, 2143-2154; doi:10.1038/npp.2010.105; published online 28 July 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据